KEITH CRANDELL
CIK 1219039 · last filed 2026-06-12
KEITH CRANDELL is a corporate insider who has filed 74 SEC Form 4 insider transactions across 20 companies since 2007. The most recent filing, for MASS, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$395.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $690.4M across reported positions. 113 SEC filings were submitted jointly with CLINTON BYBEE.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$690.43M
20
74
$395.91M
Filer Profile
SUITE 1025
CHICAGO, IL 60631
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MASS | Director | 5,764,419 | $9.52 | $54.88M | $6.00M | 8 | 2026-06-12 |
| TWST | Director | 103,618 | $127.22 | $13.18M | -$11.52M | 13 | 2026-02-09 |
| NMRA | 10%+ Owner | 6,046,907 | $1.04 | $6.29M | $258.64M | 5 | 2025-10-29 |
| LYEL | 10%+ Owner | 910,317 | $11.96 | $10.89M | $0 | 1 | 2025-07-29 |
| SANA | 10%+ Owner | 12,446,022 | $3.13 | $38.96M | $40.00M | 1 | 2024-02-12 |
| QTRX | Director | 308,483 | $2.56 | $789.7K | $3.99M | 22 | 2023-04-04 |
| VIR | 10%+ Owner | 7,563,619 | $10.62 | $80.33M | $0 | 1 | 2022-09-07 |
| DA32 Life Science Tech Acquisition Corp. (DALS) Delisted | Director | 2,250,000 | $10.32 | $23.22M | $16.00M | 2 | 2021-08-09 |
| ADESTO TECHNOLOGIES Corp (IOTS) Delisted | Director | 1,177,937 | — | — | $2.00M | 6 | 2019-06-06 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 435,087 | $0.00 | $174 | -$14.59M | 2 | 2019-03-14 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | 10%+ Owner | 2,900,575 | — | — | $70.39M | 2 | 2019-02-26 |
| PULM | 17,182 | $1.41 | $24.2K | $0 | 1 | 2018-04-05 | |
| FIXX | 10%+ Owner | 37,461 | $13.72 | $513.9K | $0 | 1 | 2018-04-04 |
| DNLI | 10%+ Owner | 11,068,749 | $21.09 | $233.44M | $0 | 1 | 2017-12-12 |
| XCOM | 10%+ Owner | — | $28.61 | — | $0 | 2 | 2016-10-13 |
| PI | 10%+ Owner | 1,388,049 | $176.82 | $245.43M | $0 | 1 | 2016-07-26 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 3,187,044 | $8.68 | $27.66M | $0 | 1 | 2015-01-16 |
| FATE | 10%+ Owner | 2,473,188 | $2.31 | $5.71M | $25.00M | 1 | 2013-10-07 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | 10%+ Owner | 1,897,474 | — | — | $0 | 1 | 2012-10-16 |
| CELEBRATE EXPRESS, INC. (BDAY) Delisted | Director | — | — | — | $0 | 1 | 2007-10-23 |
Recent Filings
74 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | MASS | Mixed | +14,083 | $0 | EDGAR |
| 2026-02-09 | TWST | Grant (A) | +5,095 | $0 | EDGAR |
| 2025-10-29 | NMRA | Buy (P) | +13,409,900 | $35.00M | EDGAR |
| 2025-07-29 | LYEL | — | — | $0 | EDGAR |
| 2025-06-13 | MASS | Mixed | +11,364 | $0 | EDGAR |
| 2025-02-07 | TWST | Grant (A) | +4,472 | $0 | EDGAR |
| 2024-06-14 | MASS | Mixed | +7,777 | $0 | EDGAR |
| 2024-02-12 | SANA | Buy (P) | +7,272,724 | $40.00M | EDGAR |
| 2024-02-09 | TWST | Grant (A) | +5,815 | $0 | EDGAR |
| 2023-11-07 | NMRA | Buy (P) | +574,164 | $6.60M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.